Our perspective on AL/ML in the life sciences industry.
ADaM package generation has long been one of the most persistent bottlenecks in clinical development, often consuming over two months across specification creation, programming, and
Clinical development has never been more advanced. We can stream biomarker data in real-time, interpret complex protocols using generative Artificial Intelligence (AI), and transform clinical
Clinical data teams know this challenge all too well- creating SDTM (Study Data Tabulation Model) specifications and programming deliverables can take upwards of 8 hours
Clinical trials are experiencing a major transformation. While the core goal remains bringing safe, effective treatments to patients, how we reach that goal is changing
The stakes in clinical research have never been higher. While breakthrough treatments show tremendous promise, the reality is sobering: bringing a single drug to market
Clinical trials are under more pressure than ever to move fast; yet documentation remains a stubborn bottleneck. According to the NIH, documentation delays contribute to
In our previous blog, we took an in-depth look at AI hallucinations, including what they are, why they matter, and how they can be measured.
At Saama, our mission is to empower life sciences companies with advanced AI-driven solutions that improve human health. We believe that by enabling faster, more
